Therapeutic targeting of telomerase

Genes

Volumn 7, Issue 7, 2016, Pages

  Jäger, Kathrin ^a   Walter, Michael ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

Aging; Atherosclerosis; Cancer; Gene therapy; Immunotherapy; Personalized medicine; Regenerative medicine; Senescence; Telomerase; Telomeres

Indexed keywords

ANTINEOPLASTIC AGENT; OLIGONUCLEOTIDE INHIBITOR DERIVATIVE; PLANT MEDICINAL PRODUCT; SMALL MOLECULE TELOMERASE INHIBITOR DERIVATIVE; TELOMERASE; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; ANTIPROLIFERATIVE ACTIVITY; ATHEROSCLEROSIS; CANCER IMMUNOTHERAPY; CANCER THERAPY; ENZYME ACTIVATION; ENZYME LOCALIZATION; GENE SILENCING; GENE THERAPY; HUMAN; MENTAL DISEASE; NEOPLASM; NONHUMAN; PROTEIN EXPRESSION; PROTEIN TARGETING; REGENERATIVE MEDICINE; REVIEW; SKIN DISEASE; SKIN GRAFT; STEM CELL TRANSPLANTATION; TISSUE ENGINEERING; UPREGULATION;

EID: 84979300215     PISSN: None     EISSN: 20734425     Source Type: Journal    
DOI: 10.3390/genes7070039     Document Type: Review

References (257)

1. Walter, M. Interrelationships among HDL metabolism, aging, and atherosclerosis. Arterioscler Thromb. Vasc. Biol. 2009, 29, 1244-1250. [CrossRef] [PubMed]
2. Fyhrquist, F, Saijonmaa, O, Strandberg, T. The roles of senescence and telomere shortening in cardiovascular disease. Nat. Rev. Cardiol. 2013, 10, 274-283. [CrossRef] [PubMed]
3. To-Miles, F.Y.L, Backman, C.L. What telomeres say about activity and health: A rapid review. Can. J. Occup. Ther. 2016. [CrossRef] [PubMed]
4. Zhu, H, Blecher, M, van der Harst, P. Healthy aging and disease: Role for telomere biology? Clin. Sci. 2011, 120, 427-440. [CrossRef] [PubMed]
5. Boccardi, V, Herbig, U. Telomerase gene therapy: A novel approach to combat aging. EMBO Mol. Med. 2012. [CrossRef] [PubMed]
6. Xin, H, Liu, D, Songyang, Z. The telosome/shelterin complex and its functions. Genome Biol. 2008. [CrossRef] [PubMed]
7. De Lange, T. Shelterin: The protein complex that shapes and safeguards human telomeres. Genes Dev. 2005, 19, 2100-2110. [CrossRef] [PubMed]
8. Artandi, S.E, DePinho, R.A. Telomeres and telomerase in cancer. Carcinogenesis 2010, 31, 9-18. [CrossRef] [PubMed]
9. Sarin, K.Y, Cheung, P, Gilison, D, Lee, E, Tennen, R.I, Wang, E, Artandi, M.K, Oro, A.E, Artandi, S.E. Conditional telomerase induction causes proliferation of hair follicle stem cells. Nature 2005, 436, 1048-1052. [CrossRef] [PubMed]
10. Baker, D.J, Wijshake, T, Tchkonia, T, LeBrasseur, N.K, Childs, B.G, van de Sluis, B, Kirkland, J.L, van Deursen, J.M. Clearance of p16Ink4apositive senescent cells delays ageing associated disorders. Nature 2001, 479, 232-236. [CrossRef] [PubMed]
11. Stanley, S.E, Armanios, M. The short and long telomere syndromes: Paired paradigms for molecular medicine. Curr. Opin. Gen. Dev. 2015, 33, 1-9. [CrossRef] [PubMed]
12. Park, J.I, Venteicher, A.S, Hong, J.Y, Choi, J, Jun, S, Shkreli, M, Chang, W, Meng, Z, Cheung, P, Ji, H, et al. Telomerase modulates Wnt signalling by association with target gene chromatin. Nature 2009, 460, 66-72. [CrossRef] [PubMed]
13. Rao, T.P, Kuhl, M. An updated overview on Wnt signaling pathways: A prelude for more. Circ. Res. 2010, 106, 1798-1806. [CrossRef] [PubMed]
14. Von Zglinicki, T. Oxidative stress shortens telomeres. Trends Biochem. Sci. 2001, 27, 339-344. [CrossRef]
15. Nazari-Shafti, T.Z, Cooke, J.P. Telomerase therapy to reserve cardiovascular senescence. Methodist Debakey Cardiovasc. J. 2015, 11, 172-175. [CrossRef] [PubMed]
16. Babizhayev, M.A, Yegorov, Y.E. Tissue formation and tissue engineering through host cell recruitment or a potential injectable cell-based biocomposite with replicative potential: Molecular mechanisms controlling cellular senescence and the involvement of controlled transient telomerase activation therapies. J. Biomed. Mater. Res. Part A 2015, 103A, 3993-4023.
17. Xu, D, Erickson, S, Szeps, M, Gruber, A, Sangfelt, O, Einhorn, S, Pisa, P, Grandér, D. Interferon α down-regulates telomerase reverse transcriptase and telomerase activity in human malignant and nonmalignant hematopoietic cells. Blood 2000, 96, 4313-4318. [PubMed]
18. Aviv, A, Valdes, A, Gardner, J.P, Swaminathan, R, Kimura, M, Spector, T.D. Menopause modifies the association of leukocyte telomere length with insulin resistance and inflammation. J. Clin. Endocrinol. Metab. 2006, 91, 635-640. [CrossRef] [PubMed]
19. Carrero, J.J, Stenvinkel, P, Fellstrom, B, Qureshi, A.R, Lamb, K, Heimbürger, O, Bárány, P, Radhakrishnan, K, Lindholm, B, Soveri, I, et al. Telomere attrition is associated with inflammation, low fetuin—a levels and high mortality in prevalent haemodialysis patients. J. Intern. Med. 2008, 263, 302-312. [CrossRef] [PubMed]
20. Deng, W, Cheung, S.T, Tsao, S.W, Wang, X.M, Tiwari, A.F. Telomerase activity and its association with psychological stress, mental disorders, lifestyle factors and interventions: A systematic review. Psychoneuroendocrinology 2016, 64, 150-163. [CrossRef] [PubMed]
21. Oliveira, B.S, Zunzunegui, M.V, Quinlan, J, Fahmi, H, Tu, M.T, Guerra, R.O. Systematic review of the association between chronic social stress and telomere length: A life course perspective. Ageing Res. Rev. 2016, 26, 37-52. [CrossRef] [PubMed]
22. Nawrot, T.S, Staessen, J.A, Holvoet, P, Struijker-Boudier, H.A, Schiffers, P, van Bortel, L.M, Fagard, R.H, Gardner, J.P, Kimura, M, Aviv, A. Telomere length and its associations with oxidized-LDL, carotid artery distensibility and smoking. Front. Biosci. 2010, 2, 1164-1168.
23. Yaswen, P, MacKenzieb, K.L, Keithc, W.N, Hentosh, P, Rodier, F, Zhu, J, Firestone, G.L, Matheu, A, Carnero, A, Bilsland, A, et al. Therapeutic targeting of replicative immortality. Sem. Cancer Biol. 2015, 35, S104-S128. [CrossRef] [PubMed]
24. Jacobs, J.J.L, de Lange, T. Significant Role for p16INK4a in p53-Independent Telomere-Directed Senescence. Curr. Biol. 2004, 14, 2302-2308. [CrossRef] [PubMed]
25. Jacobs, J.J.L. Loss of Telomere Protection: Consequences and Opportunities. Front. Oncol. 2013. [CrossRef] [PubMed]
26. Chang, S, Khoo, C.M, Naylor, M.L, Maser, R.S, DePinho, R.A. Telomere-based crisis: Functional differences between telomerase activation and ALT in tumor progression. Genes Dev. 2003, 17, 88-100. [CrossRef] [PubMed]
27. Hu, J, Hwang, S.S, Liesa, M, Gan, B, Sahin, E, Jaskelioff, M, Ding, Z, Ying, H, Boutin, A.T, Zhang, H, et al. Antitelomerase Therapy Provokes ALT and Mitochondrial Adaptive Mechanisms in Cancer. Cell 2012, 148, 651-663. [CrossRef] [PubMed]
28. O’Sullivan, R, Almouzni, G. Assembly of telomeric chromatin to create ALTernative endings. Trends Cell Biol. 2014, 24, 675-685. [CrossRef] [PubMed]
29. Zhang, A, Zheng, C, Lindvall, C, Hou, M, Ekedahl, J, Lewensohn, R, Yan, Z, Yang, X, Henriksson, M, Blennow, E, et al. Frequent Amplification of the Telomerase Reverse Transcriptase Gene in Human Tumors. Cancer Res. 2000, 60, 6230-6235. [PubMed]
30. Zhang, A, Zheng, C, Hou, M, Lindvall, C, Wallin, K.L, Angström, T, Yang, X, Hellström, A.C, Blennow, E, Björkholm, M, et al. Amplification of the Telomerase Reverse Transcriptase (hTERT) Gene in Cervical Carcinomas. Genes Chromos. Cancer 2002, 34, 269-275. [CrossRef] [PubMed]
31. Takuma, Y, Nouso, K, Kobayashi, Y, Nakamura, S, Tanaka, H, Matsumoto, E, Fujikawa, T, Suzuki, M, Hanafusa, T, Shiratori, Y. Telomerase reverse transcriptase gene amplification in hepatocellular carcinoma. J. Gastroenterol. Hepatol. 2004, 19, 1300-1304. [CrossRef] [PubMed]
32. Rousseau, P, Autexier, C. Telomere biology: Rationale for diagnostics and therapeutics in cancer. RNA Biol. 2016, 12, 1078-1082.
33. Teralı, K, Yilmazer, A. New surprises from an old favourite: The emergence of telomerase as a key player in the regulation of cancer stemness. Biochimie 2016, 121, 170-178. [CrossRef] [PubMed]
34. Soder, A.I, Hoare, S.F, Muir, S, Going, J.J, Parkinson, E.K, Keith, W.N. Amplification, increased dosage and in situ expression of the telomerase RNA gene in human cancer. Oncogene 1997, 14, 1013-1021. [CrossRef] [PubMed]
35. Shay, J.W, Wright, W.E. Hallmarks of telomeres in ageing research. J. Pathol. 2007, 211, 114-123. [CrossRef] [PubMed]
36. Sahin, E, Depinho, R.A. Linking functional decline of telomeres, mitochondria and stem cells during ageing. Nature 2010, 464, 520-528. [CrossRef] [PubMed]
37. Shay, J.W, Wright, W.E. Use of telomerase to create bioengineered tissues. Ann. N. Y. Acad. Sci. 2005, 1057, 479-491. [CrossRef] [PubMed]
38. Jaskelioff, M, Muller, F.L, Paik, J.H, Thomas, E, Jiang, S, Adams, A.C, Sahin, E, Kost-Alimova, M, Protopopov, A, Cadiñanos, J, et al. Telomerase reactivation reverses tissue degeneration in aged telomerase-deficient mice. Nature 2011, 469, 102-106. [CrossRef] [PubMed]
39. Allsopp, R.C, Weissman, I.L. Replicative senescence of hematiopoietic stem cells during serial transplantation: Does telomere shortening play a role? Oncogene 2002, 21, 3270-3273. [CrossRef] [PubMed]
40. Pendino, F, Tarkanyi, I, Dudognon, C, Hillion, J, Lanotte, M, Aradi, J, Segal-Bendirdjian, S. Telomeres and telomerase: Pharmacological targets for new anticancer strategies? Curr. Cancer Drug Targets 2006, 6, 147-180. [CrossRef] [PubMed]
41. Atkinson, S.P, Hoare, S.F, Glasspool, R.M, Keith, W.N. Lack of telomerase gene expression in alternative lengthening of telomere cells is associated with chromatin remodeling of the hTR and hTERT gene promoters. Cancer Res. 2005, 65, 7585-7590. [PubMed]
42. Serenicki, N, Hoare, S.F, Kassem, M, Atkinson, S.P, Keith, W.N. Telomerase promoter reprogramming and interaction with general transcription factors in the human mesenchymal stem cell. Regen. Med. 2006, 1, 125-131.
43. Doshida, M, Ohmichi, M, Tsutsumi, S, Kawagoe, J, Takahashi, T, Du, B, Mori-Abe, A, Ohte, T, Saitoh-Sekiguchi, M, Takahashi, K, et al. Raloxifene increases proliferation and up-regulates telomerase activity in human umbilical vein endothelial cells. J. Biol. Chem. 2006, 281, 24270-24278. [CrossRef] [PubMed]
44. Liu, K, Hodes, R.J, Weng, N. Cutting edge: Telomerase activation in human T lymphocytes does not require increase in telomerase reverse transcriptase (hTERT) protein but is associated with hTERT phosphorylation and nuclear translocation. J. Immunol. 2001, 166, 4826-4830. [CrossRef] [PubMed]
45. Tarkanyi, I, Aradi, J. Pharmacological intervention strategies for affecting telomerase activity: Future prospects to treat cancer and degenerative disease. Biochemie 2008, 90, 156-172. [CrossRef] [PubMed]
46. Stewart, S.A. Multiple levels of telomerase regulation. Mol. Interv. 2002, 2, 481-483. [CrossRef] [PubMed]
47. Sharma, N.K, Reyes, A, Green, P, Caron, M.J, Bonini, M.G, Gordon, D.M, Holt, I.J, Santos, J.H. Human telomerase acts as a hTR-independent reverse transcriptase in mitochondria. Nucleic Acids Res. 2012, 40, 712-725. [CrossRef] [PubMed]
48. Bodnar, A.G, Ouellette, M, Frolkis, M, Holt, S.E, Chiu, C.P, Morin, G.B, Harley, C.B, Shay, J.W, Lichtsteiner, S, Wright, W.E. Extension of life-span by introduction of telomerase into normal human cells. Science 1998, 279, 349-352. [CrossRef] [PubMed]
49. Counter, C.M, Meyerson, M, Eaton, E.N, Ellisen, L.W, Caddle, S.D, Haber, D.A, Weinberg, R.A. Telomerase activity is restored in human cells by ectopic expression of hTERT (hEST2), the catalytic subunit of telomerase. Oncogene 1998, 16, 1217-1222. [CrossRef] [PubMed]
50. Vaziri, H, Benchimol, S. Reconstitution of telomerase activity in normal human cells leads to elongation of telomeres and extended replicative life span. Curr. Biol. 1998, 8, 279-282. [CrossRef]
51. Jiang, X.R, Jimenez, G, Chang, E, Frolkis, M, Kusler, B, Sage, M, Beeche, M, Bodnar, A.G, Wahl, G.M, Tlsty, T.D, et al. Telomerase expression in human somatic cells does not induce changes associated with a transformed phenotype. Nat. Genet. 1999, 21, 111-114. [CrossRef] [PubMed]
52. Morales, C.P, Holt, S.E, Ouellette, M, Kaur, K.J, Yan, Y, Wilson, K.S, White, M.A, Wright, W.E, Shay, J.W. Absence of cancer-associated changes in human fibroblasts immortalized with telomerase. Nat. Genet. 1999, 21, 115-118. [CrossRef] [PubMed]
53. Funk, W.D, Wang, C.K, Shelton, D.N, Harley, C.B, Pagon, G.D, Hoeffler, W.K. Telomerase expression restores dermal integrity to in vitro-aged fibroblasts in a reconstituted skin model. Exp. Cell Res. 2000, 258, 270-278. [CrossRef] [PubMed]
54. Wyllie, F.S, Jones, C.J, Skinner, J.W, Haughton, M.F, Wallis, C, Wynford-Thomas, D, Faragher, R.G, Kipling, D. Telomerase prevents the accelerated cell ageing ofWerner syndrome fibroblasts. Nat. Genet. 2000, 24, 16-17. [PubMed]
55. Harada, H, Nakagawa, H, Takaoka, M, Lee, J, Herlyn, M, Diehl, J.A, Rustgi, A.K. Cleavage of MCM2 licensing protein fosters senescence in human keratinocytes. Cell Cycle 2008, 7, 3534-3538. [CrossRef] [PubMed]
56. McKee, J.A, Banik, S.S, Boyer, M.J, Hamad, N.M, Lawson, J.H, Niklason, L.E, Counter, C.M. Human arteries engineered in vitro. EMBO Rep. 2003, 4, 633-638. [CrossRef] [PubMed]
57. Oh, H, Taffet, G.E, Youker, K.A, Entman, M.L, Overbeek, P.A, Michael, L.H, Schneider, M.D. Telomerase reverse transcriptase promotes cardiac muscle cell proliferation, hypertrophy, and survival. Proc. Natl. Acad. Sci. USA 2001, 98, 10308-10313. [CrossRef] [PubMed]
58. Wootton, M, Steeghs, K, Watt, D, Munro, J, Gordon, K, Ireland, H, Morrison, V, Behan, W, Parkinson, E.K. Telomerase alone extends the replicative life span of human skeletal muscle cells without compromising genomic stability. Hum. Gene Ther. 2003, 14, 1473-1487. [CrossRef] [PubMed]
59. Yang, J, Chang, E, Cherry, A.M, Bangs, C.D, Oei, Y, Bodnar, A, Bronstein, A, Chiu, C.P, Herron, G.S. Human endothelial cell life extension by telomerase expression. J. Biol. Chem. 1999, 274, 26141-26148. [CrossRef] [PubMed]
60. Gu, X, Zhang, J, Brann, D.W, Yu, F.S. Brain and retinal vascular endothelial cells with extended life span established by ectopic expression of telomerase. Invest. Ophthalmol. Vis. Sci. 2003, 44, 3219-3225. [CrossRef] [PubMed]
61. Yang, J, Nagavarapu, U, Relloma, K, Sjaastad, M.D, Moss, W.C, Passaniti, A, Herron, G.S. Telomerized human microvasculature is functional in vivo. Nat. Biotechnol. 2001, 19, 219-224. [CrossRef] [PubMed]
62. Condon, J, Yin, S, Mayhew, B, Word, R.A, Wright, W.E, Shay, J.W, Rainey, W.E. Telomerase immortalization of human myometrial cells. Biol. Reprod. 2002, 67, 506-514. [CrossRef] [PubMed]
63. Shi, S, Gronthos, S, Chen, S, Reddi, A, Counter, C.M, Robey, P.G, Wang, C.Y. Bone formation by human postnatal bone marrow stromal stem cells is enhanced by telomerase expression. Nat. Biotechnol. 2002, 20, 587-591. [CrossRef] [PubMed]
64. Simonsen, J.L, Rosada, C, Serakinci, N, Justesen, J, Stenderup, K, Rattan, S.I, Jensen, T.G, Kassem, M. Telomerase expression extends the proliferative life-span and maintains the osteogenic potential of human bone marrow stromal cells. Nat. Biotechnol. 2002, 20, 592-596. [CrossRef] [PubMed]
65. Gronthos, S, Chen, S, Wang, C.Y, Robey, P.G, Shi, S. Telomerase accelerates osteogenesis of bone marrow stromal stem cells by upregulation of CBFA1, osterix, and osteocalcin. J. Bone Miner Res. 2003, 18, 716-722. [CrossRef] [PubMed]
66. Kawano, Y, Kobune, M, Yamaguchi, M, Nakamura, K, Ito, Y, Sasaki, K, Takahashi, S, Nakamura, T, Chiba, H, Sato, T, et al. Ex vivo expansion of human umbilical cord hematopoietic progenitor cells using a coculture system with human telomerase catalytic subunit (hTERT)-transfected human stromal cells. Blood 2003, 101, 532-540. [CrossRef] [PubMed]
67. Darimont, C, Avanti, O, Tromvoukis, Y, Vautravers-Leone, P, Kurihara, N, Roodman, G.D, Colgin, L.M, Tullberg-Reinert, H, Pfeifer, A.M, Offord, E.A, et al. SV40 T antigen and telomerase are required to obtain immortalized human adult bone cells without loss of the differentiated phenotype. Cell Growth Differ. 2002, 13, 59-67. [PubMed]
68. Yudoh, K, Matsuno, H, Nakazawa, F, Katayama, R, Kimura, T. Reconstituting telomerase activity using the telomerase catalytic subunit prevents the telomere shorting and replicative senescence in human osteoblasts. J. Bone Miner Res. 2001, 16, 1453-1464. [CrossRef] [PubMed]
69. Yudoh, K, Nishioka, K. Telomerized presenescent osteoblasts prevent bone mass loss in vivo. Gene Ther. 2004, 11, 909-915. [CrossRef] [PubMed]
70. Hao, J, Narayanan, K, Ramachandran, A, He, G, Almushayt, A, Evans, C, George, A. Odontoblast cells immortalized by telomerase produce mineralized dentin-like tissue both in vitro and in vivo. J. Biol. Chem. 2002, 277, 19976-19981. [CrossRef] [PubMed]
71. Luiten, R.M, Pene, J, Yssel, H, Spits, H. Ectopic hTERT expression extends the life span of human CD4 helper and regulatory T-cell clones and confers resistance to oxidative stress-induced apoptosis. Blood 2003, 101, 4512-4519. [CrossRef] [PubMed]
72. Kobune, M, Kawano, Y, Ito, Y, Chiba, H, Nakamura, K, Tsuda, H, Sasaki, K, Dehari, H, Uchida, H, Honmou, O. Telomerized human multipotent mesenchymal cells can differentiate into hematopoietic and cobblestone area-supporting cells. Exp. Hematol. 2003, 31, 715-722. [CrossRef]
73. Di Donna, S, Mamchaoui, K, Cooper, R.N, Seigneurin-Venin, S, Tremblay, J, Butler-Browne, G.S, Mouly, V. Telomerase can extend the proliferative capacity of human myoblasts, but does not lead to their immortalization. Mol. Cancer Res. 2003, 1, 643-653. [PubMed]
74. Schnabl, B, Choi, Y.H, Olsen, J.C, Hagedorn, C.H, Brenner, D.A. Immortal activated human hepatic stellate cells generated by ectopic telomerase expression. Lab. Invest. 2002, 82, 323-333. [CrossRef] [PubMed]
75. Watanabe, T, Shibata, N, Westerman, K.A, Okitsu, T, Allain, J.E, Sakaguchi, M, Totsugawa, T, Maruyama, M, Matsumura, T, Noguchi, H. Establishment of immortalized human hepatic stellate scavenger cells to develop bioartificial livers. Transplantation 2003, 75, 1873-1880. [CrossRef] [PubMed]
76. Roy, N.S, Nakano, T, Keyoung, H.M, Windrem, M, Rashbaum, W.K, Alonso, M.L, Kang, J, Peng, W, Carpenter, M.K, Lin, J, et al. Telomerase immortalization of neuronally restricted progenitor cells derived from the human fetal spinal cord. Nat. Biotechnol. 2004, 22, 297-305. [CrossRef] [PubMed]
77. Townsley, D.M, Dumitriu, B, Young, N.S. Bone marrow failure and the telomeropathies. Blood 2014, 124, 2775-2783. [CrossRef] [PubMed]
78. Shay, J.W, Wright, W.E. The use of telomerized cells for tissue engineering. Nat. Biotechnol. 2000, 18, 22-23. [CrossRef] [PubMed]
79. Ulaner, G.A. Telomere Maintenance in Clinical Medicine. Am. J. Med. 2004, 117, 262-269. [CrossRef] [PubMed]
80. Bär, C, Povedano, J.M, Serrano, R, Benitez-Buelga, C, Popkes, M, Formentini, I, Bobadilla, M, Bosch, F, Blasco, M.A. Telomerase gene therapy rescues telomere length, bone marrow aplasia, and survival in mice with aplastic anemia. Blood 2016, 127, 1770-1779. [CrossRef] [PubMed]
81. Donati, B, Valenti, L. Telomeres, NAFLD and Chronic Liver Disease. Int. J. Mol. Sci. 2016. [CrossRef] [PubMed]
82. Calado, R.T. Telomeres in lung diseases. Prog. Mol. Biol. Transl. Sci. 2014, 125, 173-183. [PubMed]
83. Li, J, Pei, M. Cell senescence: A challenge in cartilage engineering and regeneration. Tissue Eng. Part B Rev. 2012, 18, 270-287. [CrossRef] [PubMed]
84. Babizhayev, M.A, Yegorov, Y.E. Telomere attrition in lens epithelial cells—A target for N-acetylcarnosine therapy. Front. Biosci. 2010, 15, 934-956. [CrossRef]
85. Weyand, C.M, Fujii, H, Shao, L, Goronzy, J.J. Rejuvenating the immune system in rheumatoid arthritis. Nat. Rev. Rheumatol. 2009, 5, 583-588. [CrossRef] [PubMed]
86. Thomas, M, Yang, L, Hornsby, P.J. Formation of functional tissue from transplanted adrenocortical cells expressing telomerase reverse transcriptase. Nat. Biotechnol. 2000, 18, 39-42. [PubMed]
87. Fauce, S.R, Jamieson, B.D, Chin, A.C, Mitsuyasu, R.T, Parish, S.T, Ng, H.L, Kitchen, C.M, Yang, O.O, Harley, C.B, Effros, R.B. Telomerase-based pharmacologic enhancement of antiviral function of human CD8+ T lymphocytes. J. Immunol. 2008, 181, 7400-7406. [CrossRef] [PubMed]
88. Dock, J.N, Effros, R.B. Role of CD8 T Cell Replicative Senescence in Human Aging and in HIV-mediated Immunosenescence. Aging Dis. 2011, 2, 382-397. [PubMed]
89. Harley, C.B, Liu, W, Blasco, M, Vera, E, Andrews, W.H, Briggs, L.A, Raffaele, J.M. A natural product telomerase activator as part of a health maintenance program. Rejuven. Res. 2011, 14, 45-56. [CrossRef] [PubMed]
90. Bernardes de Jesus, B, Schneeberger, K, Vera, E, Tejera, A, Harley, C.B, Blasco, M.A. The telomerase activator TA-65 elongates short telomeres and increases health span of adult/old mice without increasing cancer incidence. Aging Cell 2011, 10, 604-621. [CrossRef] [PubMed]
91. Dow, C.T, Harley, C.B. Evaluation of an oral telomerase activator for early age-related macular degeneration—A pilot study. Clin. Ophthalmol. 2016, 10, 243-249. [CrossRef] [PubMed]
92. Harley, C.B, Liu, W, Flom, P.L, Raffaele, J.M. A natural product telomerase activator as part of a health maintenance program: Metabolic and cardiovascular response. Rejuven. Res. 2013, 16, 386-395. [CrossRef] [PubMed]
93. Salvador, L, Singaravelu, G, Harley, C.B, Flom, P, Suram, A, Raffaele, J.M. A Natural Product Telomerase Activator Lengthens Telomeres in Humans: A Randomized, Double Blind, and Placebo Controlled Study. Rejuven. Res. 2016. [CrossRef] [PubMed]
94. Pearce, V.P, Sherrell, J, Lou, Z, Kopelovich, L, Wright, W.E, Shay, J.W. Immortalization of epithelial progenitor cells mediated by resveratrol. Oncogene 2008, 27, 2365-2374. [CrossRef] [PubMed]
95. Xia, L, Wang, X.X, Hu, X.S, Guo, X.G, Shang, Y.P, Chen, H.J, Zeng, C.L, Zhang, F.R, Chen, J.Z. Resveratrol reduces endothelial progenitor cells senescence through augmentation of telomerase activity by vAkt-dependent mechanisms. Br. J. Pharmacol. 2008, 155, 387-394. [CrossRef] [PubMed]
96. Sprouse, A.A, Steding, C.E, Herbert, B.-S. Pharmaceutical regulation of telomerase and its clinical potential. J. Cell. Mol. Med. 2012, 16, 1-7. [CrossRef] [PubMed]
97. Eitan, E, Tichon, A, Gazit, A, Gitler, D, Slavin, S, Priel, E. Novel telomerase-increasing compound in mouse brain delays the onset of amyotrophic lateral sclerosis. EMBO Mol. Med. 2012, 4, 313-329. [CrossRef] [PubMed]
98. Wang, F, Chang, G, Geng, X. NGF and TERT co-transfected BMSCs improve the restoration of cognitive impairment in vascular dementia rats. PLoS ONE 2014, 9, e98774. [CrossRef] [PubMed]
99. Haendeler, J, Hoffman, J, Diehl, J.F, Vasa, M, Spyridopoulos, I, Zeiher, A.M, Dimmeler, S. Antioxidants inhibit nuclear export of telomerase reverse transcriptase and delay replicative senescence of endothelial cells. Circ. Res. 2004, 94, 768-775. [CrossRef] [PubMed]
100. Tanaka, Y, Moritoh, Y, Miva, N. Age-dependent telomere-shortening is repressed by phosphorylated alpha-tocopherol together with cellular longevity and intracellular oxidative-stress reduction in human brain microvascular endotheliocytes. J. Cell Biochem. 2007, 102, 689-703. [CrossRef] [PubMed]
101. Passos, J.F, Saretzki, G, Ahmed, S, Nelson, G, Richter, T, Peters, H, Wappler, I, Birket, M.J, Harold, G, Schaeuble, K, et al. Mitochondrial dysfunction accounts for the stochastic heterogeneity in telomere-dependent senescence. PLoS Biol. 2007, 5, e110. [CrossRef] [PubMed]
102. Brouilette, S.W, Moore, J.S, McMahon, A.D, Thompson, J.R, Ford, I, Shepherd, J, Packard, C.J, Samani, N.J. Telomere length, risk of coronary heart disease, and statin treatment in the West of Scotland Primary Prevention Study: A nested case-control study. Lancet 2007, 369, 107-114. [CrossRef]
103. Spyridopoulos, I, Haendeler, J, Urbich, C, Brummendorf, T.H, Oh, H, Schneider, M.D, Zeiher, A.M, Dimmeler, S. Statins enhance migratory capacity by upregulation of the telomere repeat binding factor TRF2 in endothelial progenitor cells. Circulation 2004, 110, 3136-3142. [CrossRef] [PubMed]
104. Dong, X.X, Hui, Y.J, Xiang, W.X, Rong, Z.F, Jian, S, Zhu, C.J. Ginkgo Biloba extract reduces endothelial progenitor-cell senescence trough augmentation of telomerase activity. J. Cardiovasc. Pharmacol. 2007, 49, 111-115. [CrossRef] [PubMed]
105. Mimeault, M, Batra, S.K. Recent advances on the significance of stem cells in tissue regeneration and cancer therapies. Stem Cells 2006, 24, 2319-2345. [CrossRef] [PubMed]
106. Yoshikawa, T, Mitsuno, H, Nonaka, I, Sen, Y, Kawanishi, K, Inada, Y, Takakura, Y, Okuchi, K, Nonomura, A. Wound therapy by marrow mesenchymal cell transplantation. Plast. Reconstr. Surg. 2008, 121, 860-877. [CrossRef] [PubMed]
107. Kung, E.F, Wang, F, Schechner, J.S. In vivo perfusion of human skin substitutes with microvessels formed by adult circulating endothelial progenitor cells. Dermatol. Surg. 2008, 34, 137-146. [PubMed]
108. Zhang, C.P, Fu, X.B. Therapeutic potential of stem cells in skin repair and regeneration. Chin. J. Traumatol. 2008, 11, 209-221. [CrossRef]
109. Park, B.S, Jang, K.A, Sung, J.H, Park, J.S, Kwon, Y.H, Kim, K.J, Kim, W.S. Adipose-derived stem cells and their secretory factors as a promising therapy for skin aging. Dermatol. Surg. 2008, 34, 1323-1326. [PubMed]
110. Branski, L.K, Gauglitz, G.G, Herndon, D.N, Jeschke, M.G. A review of gene and stem cell therapy in cutaneous wound healing. Burns 2008, 35, 171-180. [CrossRef] [PubMed]
111. Kim, D.S, Cho, H.J, Yang, S.K, Shin, J.W, Huh, C.H, Park, K.C. IGFBP-2 Contributes to the proliferation of less proliferative cells in forming skin equivalents. Tissue Eng. Part A 2009, 15, 1075-1080. [CrossRef] [PubMed]
112. Siegl-Cachedenier, I, Flores, I, Klatt, P, Blasco, M.A. Telomerase reverses epidermal hair follicle stem cell defects and loss of longterm survival associated with critically short telomeres. J. Cell Biol. 2007, 179, 277-290. [CrossRef] [PubMed]
113. Wu, Y, Wang, J, Scott, P.G, Tredget, E.E. Bone marrow-derived stem cells in wound healing: A review. Wound Repair Regen. 2007, 15, S18-S26. [CrossRef] [PubMed]
114. Jan, H.M, Wei, M.F, Peng, C.L, Lin, S.J, Lai, P.S, Shieh, M.J. The use of polyethylenimine-DNA to topically deliver hTERT to promote hair growth. Gene Ther. 2012, 19, 86-93. [CrossRef] [PubMed]
115. Shim, J.H, Lee, T.R, Shin, D.W. Novel in vitro culture condition improves the stemness of human dermal stem/progenitor cells. Mol. Cells 2013, 36, 556-563. [CrossRef] [PubMed]
116. Neuner, B, Lenfers, A, Kelsch, R, Jäger, K, Brüggmann, N, van der Harst, P, Walter, M. Telomere length is not related to established cardiovascular risk factors but does correlate with red and white blood cell counts in a German blood donor population. PLoS ONE 2015, 10, e0139308. [CrossRef] [PubMed]
117. Walter, M, Forsyth, N.R, Wright, W, Shay, J.W, Roth, M.G. The establishment of telomerase-immortalized Tangier disease cell lines indicates the existence of an apolipoprotein A-I-inducible but ABCA1-independent cholesterol efflux pathway. J. Biol. Chem. 2004, 279, 20866-20873. [CrossRef] [PubMed]
118. Kannenberg, F, Gorzelniak, K, Jäger, K, Fobker, M, Rust, S, Repa, J, Roth, M, Björkhem, I, Walter, M. Characterization of cholesterol homeostasis in telomerase-immortalized Tangier disease fibroblasts reveals marked phenotype variability. J. Biol. Chem. 2013, 288, 36936-36947. [CrossRef] [PubMed]
119. Hartwig, F.P, Nedel, F, Collares, T.V, Tarquinio, S.B, Nör, J.E, Demarco, F.F. Telomeres and tissue engineering: The potential roles of TERT in VEGF-mediated angiogenesis. Stem Cell Rev. 2012, 8, 1275-1281. [CrossRef] [PubMed]
120. Matsushita, H, Chang, E, Glassford, A.J, Cooke, J.P, Chiu, C.P, Tsao, P.S. eNOS Activity Is Reduced in Senescent Human Endothelial Cells Preservation by hTERT Immortalization. Circ. Res. 2001, 89, 793-798. [CrossRef] [PubMed]
121. Zhou, Q.G, Hu, Y, Wu, D.L, Zhu, L.J, Chen, C, Jin, X, Luo, C.X, Wu, H.Y, Zhang, J, Zhu, D.Y. Hippocampal telomerase is involved in the modulation of depressive behaviors. J. Neurosci. 2011, 31, 12258-12269. [CrossRef] [PubMed]
122. Wolkowitz, O.M, Mellon, S.H, Epel, E.S, Lin, J, Reus, V.I, Rosser, R, Burke, H, Compagnone, M, Nelson, J.C, Dhabhar, F.S, et al. Resting leukocyte telomerase activity is elevated in major depression and predicts treatment response. Mol. Psychiatry 2012, 17, 164-172. [CrossRef] [PubMed]
123. Simon, N.M, Walton, Z.E, Bui, E, Prescott, J, Hoge, E, Keshaviah, A, Schwarz, N, Dryman, T, Ojserkis, R.A, Kovachy, B, et al. Telomere length and telomerase in a well-characterized sample of individuals with major depressive disorder compared to controls. Psychoneuroendocrinology 2015, 58, 9-22. [CrossRef] [PubMed]
124. Wei, Y.B, Backlund, L, Wegener, G, Mathé, A.A, Lavebratt, C. Telomerase dysregulation in the hippocampus of a rat model of depression. Normalization by lithium. Int. J. Neuropsychopharmacol. 2015. [CrossRef] [PubMed]
125. Martinsson, L, Wei, Y, Xu, D, Melas, P.A, Mathé, A.A, Schalling, M, Lavebratt, C, Backlund, L. Long-term lithium treatment in bipolar disorder is associated with longer leukocyte telomeres. Transl. Psychiatry 2013. [CrossRef] [PubMed]
126. Yu, W.Y, Chang, H.W, Lin, C.H, Cho, C.L. Short telomeres in patients with chronic schizophrenia who show a poor response to treatment. J. Psychiatry Neurosci. 2008, 33, 244-247. [PubMed]
127. Bersani, F.S, Lindqvist, D, Mellon, S.H, Penninx, B.W, Verhoeven, J.E, Révész, D, Reus, V.I, Wolkowitz, O.M. Telomerase activation as a possible mechanism of action for psychopharmacological interventions. Drug Discov. Today 2015, 20, 1305-1309. [CrossRef] [PubMed]
128. Duman, R.S, Malberg, J, Nakagawa, S. Regulation of adult neurogenesis by psychotropic drugs and stress. J. Pharmacol. Exp. Ther. 2001, 299, 401-407. [PubMed]
129. Kim, N.W, Piatyszek, M.A, Prowse, K.R, Harley, C.B, West, M.D, Ho, P.L, Coviello, G.M, Wright, W.E, Weinrich, S.L, Shay, J.W. Specific association of human telomerase activity with immortal cells and cancer. Science 1994, 266, 2011-2015. [CrossRef] [PubMed]
130. Podlevsky, J.D, Chen, J.J. It all comes together at the ends: Telomerase structure, function, and biogenesis. Mutat. Res. 2012, 730, 3-11. [CrossRef] [PubMed]
131. Feng, J, Funk, W.D, Wang, S.-S, Weinrich, S.L, Avilion, A.A, Chiu, C.P, Adams, R.R, Chang, E, Allsopp, R.C, Yu, J, et al. The RNA component of human telomerase. Science 1995, 269, 1236-1241. [CrossRef] [PubMed]
132. Norton, J.C, Piatyszek, M.A, Wright, W.E, Shay, J.W, Corey, D.R. Inhibition of human telomerase activity by peptide nucleic acids. Nat. Biotechnol. 1996, 14, 615-619. [CrossRef] [PubMed]
133. Kondo, S, Tanaka, Y, Kondo, Y, Hitomi, M, Barnett, G.H, Ishizaka, Y, Liu, J, Haqqi, T, Nishiyama, A, Villeponteau, B, et al. Antisense telomerase treatment: Induction of two distinct pathways, apoptosis and differentiation. FASEB J. 1988, 12, 801-811.
134. Pitts, A.E, Corey, D.R. Inhibition of human telomerase by 2’-O-methyl-RNA. Proc. Natl. Acad. Sci. USA 1988, 95, 11549-11554. [CrossRef]
135. Herbert, B, Pitts, A.E, Baker, S.I, Hamilton, S.E, Wright, W.E, Shay, J.W, Corey, D.R. Inhibition of human telomerase in immortal human cells leads to progressive telomere shortening and cell death. Proc. Natl. Acad. Sci. USA 1999, 96, 14276-14281. [CrossRef] [PubMed]
136. Corey, D.R. Telomerase inhibition, oligonucleotides, and clinical trials. Oncogene 2002, 21, 631-637. [CrossRef] [PubMed]
137. Asai, A, Oshima, Y, Yamamoto, Y, Uochi, T.A, Kusaka, H, Akinaga, S, Yamashita, Y, Pongracz, K, Pruzan, R, Wunder, E, et al. A novel telomerase template antagonist (GRN163) as a potential anticancer agent. Cancer Res. 2003, 63, 3931-3939. [PubMed]
138. Harley, C.B. Telomerase and cancer therapeutics. Nat. Rev. Cancer 2008, 8, 167-179. [CrossRef] [PubMed]
139. Marian, C.O, Cho, S.K, McEllin, B.M, Maher, E.A, Hatanpaa, K.J, Madden, C.J, Mickey, B.E, Wright, W.E, Shay, J.W, Bachoo, R.M. The telomerase antagonist, imetelstat, efficiently targets glioblastoma tumor-initiating cells leading to decreased proliferation and tumor growth. Clin. Cancer Res. 2010, 16, 154-163. [CrossRef] [PubMed]
140. Naasani, I, Seimiya, H, Yamori, T, Tsuruo, T. FJ5002: A potent telomerase inhibitor identified by exploiting the disease-oriented screening program with COMPARE analysis. Cancer Res. 1999, 59, 4004-4011. [PubMed]
141. Hayakawa, N, Nozawa, K, Ogawa, A, Kato, N, Yoshida, K, Akamatsu, K.I, Tsuchiya, M, Nagasaka, A, Yoshida, S. Isothiazolone derivatives selectively inhibit telomerase from human and rat cancer cells in vitro. Biochemistry 1999, 38, 11501-11507. [CrossRef] [PubMed]
142. Damm, K, Hemmann, U, Garin-Chesa, P, Hauel, N, Kauffmann, I, Priepke, H, Niestroj, C, Daiber, C, Enenkel, B, Guilliard, B, et al. A highly selective telomerase inhibitor limiting human cancer cell proliferation. EMBO J. 2001, 20, 6958-6968. [CrossRef] [PubMed]
143. Kleideiter, E, Piotrowska, K, Klotz, U. Screening of telomerase inhibitors. Methods Mol. Biol. 2007, 405, 167-180. [PubMed]
144. Wong, L.H, Unciti-Broceta, A, Spitzer, M, White, R, Tyers, M, Harrington, L. A yeast chemical genetic screen identifies inhibitors of human telomerase. Chem. Biol. 2013, 20, 333-340. [CrossRef] [PubMed]
145. Sengupta, S, Peterson, T.R, Sabatini, D.M. Regulation of the mTOR complex 1 pathway by nutrients, growth factors, and stress. Mol. Cell 2010, 40, 310-322. [CrossRef] [PubMed]
146. Bu, X, Jia, F, Wang, W, Guo, X, Wu, M, Wei, L. Coupled down-regulation of mTOR and telomerase activity during fluorouracil-induced apoptosis of hepatocarcinoma cells. BMC Cancer 2007. [CrossRef] [PubMed]
147. Sundin, T, Peffley, D.M, Gauthier, D, Hentosh, P. The isoprenoid perillyl alcohol inhibits telomerase activity in prostate cancer cells. Biochimie 2012, 94, 2639-2648. [CrossRef] [PubMed]
148. Sundin, T, Peffley, D.M, Hentosh, P. Disruption of an hTERT-mTOR-RAPTOR protein complex by a phytochemical perillyl alcohol and rapamycin. Mol. Cell Biochem. 2013, 375, 97-104. [CrossRef] [PubMed]
149. Liu, J.P, Chen, W, Schwarer, A.P, Li, H. Telomerase in cancer immunotherapy. Biochim. Biophys. Acta 2010, 1805, 35-42. [CrossRef] [PubMed]
150. Ugel, S, Scarselli, E, Iezzi, M, Mennuni, C, Pannellini, T, Calvaruso, F, Cipriani, B, De Palma, R, Ricci-Vitiani, L, Peranzoni, E. Autoimmune B-cell lymphopenia after successful adoptive therapy with telomerase-specific T lymphocytes. Blood 2010, 115, 1374-1384. [CrossRef] [PubMed]
151. Zanetti, M. A second chance for telomerase reverse transcriptase in anticancer immunotherapy. Nat. Rev. Clin. Oncol. 2016. [CrossRef] [PubMed]
152. Su, Z, Dannull, J, Heiser, A, Yancey, D, Pruitt, S, Madden, J, Coleman, D, Niedzwiecki, D, Gilboa, E, Vieweg, J. Immunological and clinical responses in metastatic renal cancer patients vaccinated with tumor RNA-transfected dendritic cells. Cancer Res. 2003, 63, 2127-2133. [PubMed]
153. Parkhurst, M.R, Riley, J.P, Igarashi, T, Li, Y, Robbins, P.F, Rosenberg, S.A. Immunization of patients with the hTERT: 540-548 peptide induces peptide-reactive T lymphocytes that do not recognize tumors endogenously expressing telomerase. Clin. Cancer Res. 2004, 10, 4688-4698. [CrossRef] [PubMed]
154. Vonderheide, R.H, Domchek, S.M, Schultze, J.L, George, D.J, Hoar, K.M, Chen, D.Y, Stephans, K.F, Masutomi, K, Loda, M, Xia, Z, et al. Vaccination of cancer patients against telomerase induces functional antitumor CD8+ T lymphocytes. Clin. Cancer Res. 2004, 10, 828-839. [CrossRef] [PubMed]
155. Su, Z, Dannull, J, Yang, B.K, Dahm, P, Coleman, D, Yancey, D, Sichi, S, Niedzwiecki, D, Boczkowski, D, Gilboa, E, et al. Telomerase mRNA-transfected dendritic cells stimulate antigen-specific CD8+ and CD4+ T cell responses in patients with metastatic prostate cancer. J. Immunol. 2005, 174, 3798-3807. [CrossRef] [PubMed]
156. Cortez-Gonzalez, X, Zanetti, M. Telomerase immunity from bench to bedside: Round one. J. Transl. Med. 2007. [CrossRef] [PubMed]
157. Brunsvig, P.F, Aamdal, S, Gjertsen, M.K, Kvalheim, G, Markowski-Grimsrud, C.J, Sve, I, Dyrhaug, M, Trachsel, S, Møller, M, Eriksen, J.A, et al. Telomerase peptide vaccination: A phase I/II study in patients with non-small cell lung cancer. Cancer Immunol. Immunother. 2006, 55, 1553-1564. [CrossRef] [PubMed]
158. Bernhardt, S.L, Gjertsen, M.K, Trachsel, S, Møller, M, Eriksen, J.A, Meo, M, Buanes, T, Gaudernack, G. Telomerase peptide vaccination of patients with non-resectable pancreatic cancer: A dose escalating phase I/II study. Br. J. Cancer 2006, 95, 1474-1482. [CrossRef] [PubMed]
159. Mavroudis, D, Bolonakis, I, Cornet, S, Myllaki, G, Kanellou, P, Kotsakis, A, Galanis, A, Nikoloudi, I, Spyropoulou, M, Menez, J, et al. A phase I study of the optimized cryptic peptide TERT572y in patients with advanced malignancies. Oncology 2006, 70, 306-314. [CrossRef] [PubMed]
160. Bolonaki, I, Kotsakis, A, Papadimitraki, E, Aggouraki, D, Konsolakis, G, Vagia, A, Christophylakis, C, Nikoloudi, I, Magganas, E, Galanis, A, et al. Vaccination of patients with advanced non-small-cell lung cancer with an optimized cryptic human telomerase reverse transcriptase peptide. J. Clin. Oncol. 2007, 25, 2727-2734. [CrossRef] [PubMed]
161. Berntsen, A, Trepiakas, R, Wenandy, L, Geertsen, P.F, thor Straten, P, Andersen, M.H, Pedersen, A.E, Claesson, M.H, Lorentzen, T, Johansen, J.S, et al. Therapeutic dendritic cell vaccination of patients with metastatic renal cell carcinoma: A clinical phase 1/2 trial. J. Immunother. 2008, 31, 771-780. [CrossRef] [PubMed]
162. Hunger, R.E, Kernland Lang, K, Markowski, C.J, Trachsel, S, Møller, M, Eriksen, J.A, Rasmussen, A.M, Braathen, L.R, Gaudernack, G. Vaccination of patients with cutaneous melanoma with telomerase-specific peptides. Cancer Immunol. Immunother. 2011, 60, 1553-1564. [CrossRef] [PubMed]
163. Kyte, J.A, Gaudernack, G, Dueland, S, Trachsel, S, Julsrud, L, Aamdal, S. Telomerase peptide vaccination combined with temozolomide: A clinical trial in stage IV melanoma patients. Clin. Cancer Res. 2011, 17, 4568-4580. [CrossRef] [PubMed]
164. Rapoport, A.P, Aqui, N.A, Stadtmauer, E.A, Vogl, D.T, Fang, H.B, Cai, L, Janofsky, S, Chew, A, Storek, J, Akpek, G, et al. Combination immunotherapy using adoptive T-cell transfer and tumor antigen vaccination on the basis of hTERT and survivin after ASCT for myeloma. Blood 2011, 117, 788-797. [CrossRef] [PubMed]
165. Vik-Mo, E.O, Nyakas, M, Mikkelsen, B.V, Moe, M.C, Due-Tønnesen, P, Suso, E.M, Sæbøe-Larssen, S, Sandberg, C, Brinchmann, J.E, Helseth, E, et al. Therapeutic vaccination against autologous cancer stem cells with mRNA-transfected dendritic cells in patients with glioblastoma. Cancer Immunol. Immunother. 2013, 62, 1499-1509. [CrossRef] [PubMed]
166. Fenoglio, D, Traverso, P, Parodi, A, Tomasello, L, Negrini, S, Kalli, F, Battaglia, F, Ferrera, F, Sciallero, S, Murdaca, G, et al. A multi-peptide, dual-adjuvant telomerase vaccine (GX301) is highly immunogenic in patients with prostate and renal cancer. Cancer Immunol. Immunother. 2013, 62, 1041-1052. [CrossRef] [PubMed]
167. Staff, C, Mozaffari, F, Frodin, J.E, Mellstedt, H, Liljefors, M. Telomerase (GV1001) vaccination together with gemcitabine in advanced pancreatic cancer patients. Int. J. Oncol. 2014, 45, 1293-1303. [CrossRef] [PubMed]
168. Davoli, T, de Lange, T. Telomere-driven tetraploidization occurs in human cells undergoing crisis and promotes transformation of mouse cells. Cancer Cell 2012, 21, 765-776. [CrossRef] [PubMed]
169. Greten, T.F, Forner, A, Korangy, F, N'Kontchou, G, Barget, N, Ayuso, C, Ormandy, L.A, Manns, M.P, Beaugrand, M, Bruix, J. A phase II open label trial evaluating safety and efficacy of a telomerase peptide vaccination in patients with advanced hepatocellular carcinoma. BMC Cancer 2010. [CrossRef] [PubMed]
170. Brunsvig, P.F, Kyte, J.A, Kersten, C, Sundstrøm, S, Møller, M, Nyakas, M, Hansen, G.L, Gaudernack, G, Aamdal, S. Telomerase peptide vaccination in NSCLC: A phase II trial in stage III patients vaccinated after chemoradiotherapy and an 8-year update on a phase I/II trial. Clin. Cancer Res. 2001, 17, 6847-6857. [CrossRef] [PubMed]
171. Ellebaek, E, Engell-Noerregaard, L, Iversen, T.Z, Froesig, T.M, Munir, S, Hadrup, S.R, Andersen, M.H, Svane, I.M. Metastatic melanoma patients treated with dendritic cell vaccination, interleukin-2 and metronomic cyclophosphamide: Results from a phase II trial. Cancer Immunol. Immunother. 2012, 61, 1791-1804. [CrossRef] [PubMed]
172. Kotsakis, A, Vetsika, E.K, Christou, S, Hatzidaki, D, Vardakis, N, Aggouraki, D, Konsolakis, G, Georgoulias, V, Christophyllakis, C, Cordopatis, P, et al. Clinical outcome of patients with various advanced cancer types vaccinated with an optimized cryptic human telomerase reverse transcriptase (TERT) peptide: Results of an expanded phase II study. Ann. Oncol. 2012, 23, 442-449. [CrossRef] [PubMed]
173. Middleton, G, Silcocks, P, Cox, T, Valle, J, Wadsley, J, Propper, D, Coxon, F, Ross, P, Madhusudan, S, Roques, T, et al. Gemcitabine and capecitabine with or without telomerase peptide vaccine GV1001 in patients with locally advanced or metastatic pancreatic cancer (TeloVac): An open-label, randomised, phase 3 trial. Lancet Oncol. 2014, 15, 829-840. [CrossRef]
174. Mizukoshi, E, Nakagawa, H, Kitahara, M, Yamashita, T, Arai, K, Sunagozaka, H, Iida, N, Fushimi, K, Kaneko, S. Phase I trial of multidrug resistance-associated protein 3-derived peptide in patients with hepatocellular carcinoma. Cancer Lett. 2015, 369, 242-249. [CrossRef] [PubMed]
175. Nemunaitis, J, Tong, A.W, Nemunaitis, M, Senzer, N, Phadke, A.P, Bedell, C, Adams, N, Zhang, Y.A, Maples, P.B, Chen, S, et al. A phase I study of telomerase-specific replication competent oncolytic adenovirus (telomelysin) for various solid tumours. Mol. Ther. 2010, 18, 429-434. [CrossRef] [PubMed]
176. Keith, W.N, Bilsland, A, Hardie, M, Evans, T.R. Drug insight: Cancer cell immortality-telomerase as a target for novel cancer gene therapies. Nat. Clin. Pract. Oncol. 2004, 1, 88-96. [CrossRef] [PubMed]
177. Chen, Y, Zhang, Y. Functional and mechanistic analysis of telomerase: An antitumor drug target. Pharmacol. Ther. 2016, 163, 24-47. [CrossRef] [PubMed]
178. Sun, L, Wang, X. Effects of allicin on both telomerase activity and apoptosis in gastric cancer SGC-7901 cells. World J. Gastroenterol. 2003, 9, 1930-1934. [CrossRef] [PubMed]
179. Chakraborty, S, Ghosh, U, Bhattacharyya, N.P, Bhattacharya, R.K, Roy, M. Inhibition of telomerase activity and induction of apoptosis by curcumin in K-562 cells. Mutat. Res. 2006, 596, 81-90. [CrossRef] [PubMed]
180. Yokoyama, M, Noguchi, M, Nakao, Y, Ysunaga, M, Yamasaki, F, Iwasaka, T. Antiproliferative effects of the major tea polyphenol, (-)-epigallocatechin gallate and retinoic acid in cervical adenocarcinoma. Gynecol Oncol. 2008, 108, 326-331. [CrossRef] [PubMed]
181. Ramachandran, C, Fonseca, H.B, Jhabvala, P, Escalon, E.A, Melnick, S.J. Curcumin inhibits telomerase activity through human telomerase reverse transcritpase in MCF-7 breast cancer cell line. Cancer Lett. 2002, 184, 1-6. [CrossRef]
182. Hsin, I.L, Sheu, G.T, Chen, H.H, Chiu, L.Y, Wang, H.D, Chan, H.W, Hsu, C.P, Ko, J.L. N-acetyl cysteine mitigates curcumin-mediated telomerase inhibition through rescuing of Sp1 reduction in A549 cells. Mutat. Res. 2010, 688, 72-77. [CrossRef] [PubMed]
183. Lee, J.H, Chung, I.K. Curcumin inhibits nuclear localization of telomerase by dissociating the Hsp90 co-chaperone p23 from hTERT. Cancer Lett. 2010, 290, 76-86. [CrossRef] [PubMed]
184. Singh, M, Singh, N. Molecular mechanism of curcumin induced cytotoxicity in human cervical carcinoma cells. Mol. Cell Biochem. 2009, 325, 107-119. [CrossRef] [PubMed]
185. Mukherjee Nee Chakraborty, S, Ghosh, U, Bhattacharyya, N.P, Bhattacharya, R.K, Dey, S, Roy, M. Curcumin-induced apoptosis in human leukemia cell HL-60 is associated with inhibition of telomerase activity. Mol. Cell Biochem. 2007, 297, 31-39. [CrossRef] [PubMed]
186. Berletch, J.B, Liu, C, Love, W.K, Andrews, L.G, Katiyar, S.K, Tollefsbol, T.O. Epigenetic and genetic mechanisms contribute to telomerase inhibition by EGCG. J. Cell Biochem. 2008, 103, 509-519. [CrossRef] [PubMed]
187. Li, Y, Liu, L, Andrews, L.G, Tollefsbol, T.O. Genistein depletes telomerase activity through cross-talk between genetic and epigenetic mechanisms. Int. J. Cancer 2009, 125, 286-296. [CrossRef] [PubMed]
188. Meeran, S.M, Patel, S.N, Chan, T.H, Tollefsbol, T.O. A novel prodrug of epigallocatechin-3-gallate: Differential epigenetic hTERT repression in human breast cancer cells. Cancer Prev. Res. (Phila) 2011, 4, 1243-1254. [CrossRef] [PubMed]
189. Moon, D.O, Kang, S.H, Kim, K.C, Kim, M.O, Choi, Y.H, Kim, G.Y. Sulforaphane decreases viability and telomerase activity in hepatocellular carcinoma Hep3B cells through the reactive oxygen species-dependent pathway. Cancer Lett. 2010, 295, 260-266. [CrossRef] [PubMed]
190. Mittal, A, Pate, M.S, Wylie, R.C, Tollefsbol, T.O, Katiyar, S.K. EGCG down-regulates telomerase in human breast carcinoma MCF-7 cells, leading to suppression of cell viability and induction of apoptosis. Int. J. Oncol. 2004, 24, 703-710. [CrossRef] [PubMed]
191. Shapira, S, Granot, G, Mor-Tzuntz, R, Raanani, P, Uziel, O, Lahav, M, Shpilberg, O. Second-generation tyrosine kinase inhibitors reduce telomerase activity in K562 cells. Cancer Lett. 2012, 323, 223-231. [CrossRef] [PubMed]
192. Mor-Tzuntz, R, Uziel, O, Shpilberg, O, Lahav, J, Raanani, P, Bakhanashvili, M, Rabizadeh, E, Zimra, Y, Lahav, M, Granot, G. Effect of imatinib on the signal transduction cascade regulating telomerase activity in K562 (BCR-ABL-positive) cells sensitive and resistant to imatinib. Exp. Hematol. 2010, 8, 27-37. [CrossRef] [PubMed]
193. Moon, D.O, Kim, M.O, Heo, M.S, Lee, J.D, Choi, Y.H, Kim, G.Y. Gefitinib induces apoptosis and decreases telomerase activity in MDA-MB-231 human breast cancer cells. Arch. Pharm. Res. 2009, 32, 1351-1360. [CrossRef] [PubMed]
194. Zhang, Y, Sun, M, Shi, W, Yang, Q, Chen, C, Wang, Z, Zhou, X. Arsenic trioxide suppresses transcription of hTERT through down-regulation ofmultiple transcription factors in HL-60 leukemia cells. Toxicol. Lett. 2015, 232, 481-489. [CrossRef] [PubMed]
195. Zhang, X, Li, B, de Jonge, N, Bjorkholm, M, Xu, D. The DNA methylation inhibitor induces telomere dysfunction and apoptosis of leukemia cells that is attenuated by telomerase over-expression. Oncotarget 2015, 6, 4888-4900. [CrossRef] [PubMed]
196. Kanzawa, T, Germano, I.M, Kondo, Y, Ito, H, Kyo, S, Kondo, S. Inhibition of telomerase activity in malignant glioma cells correlates with their sensitivity to temozolomide. Br. J. Cancer 2003, 89, 922-929. [CrossRef] [PubMed]
197. Gan, Y, Lu, J, Yeung, B.Z, Cottage, C.T, Wientjes, M.G, Au, J.L. Pharmacodynamics of telomerase inhibition and telomere shortening by noncytotoxic suramin. AAPS J. 2015, 17, 268-276. [CrossRef] [PubMed]
198. He, H, Xia, H.H, Wang, J.D, Gu, Q, Lin, M.C, Zou, B, Lam, S.K, Chan, A.O, Yuen, M.F, Kung, H.F, et al. Inhibition of human telomerase reverse transcriptase by nonsteroidal antiinflammatory drugs in colon carcinoma. Cancer 2006, 106, 1243-1249. [CrossRef] [PubMed]
199. Zhao, Y.-Q, Feng, H.-W, Jia, T, Chen, X.-M, Zhang, H, Xu, A.-T, Zhang, H.L, Fan, X.-L. Antiproliferative effects of celecoxib in Hep-2 cells through telomerase inhibition and induction of apoptosis. Asian Pac. J. Cancer Prev. 2014, 15, 4919-4923. [CrossRef] [PubMed]
200. Rashid-Kolvear, F, Taboski, M.A, Nguyen, J, Wang, D.Y, Harrington, L.A, Done, S.J. Troglitazone suppresses telomerase activity independently of PPARgamma in estrogen-receptor negative breast cancer cells. BMC Cancer 2011. [CrossRef]
201. Kiran, K.G, Palaniswamy, M, Angayarkanni, J. Human telomerase inhibitors from microbial source. World J. Microbiol. Biotechnol. 2015, 31, 1329-1341. [CrossRef] [PubMed]
202. Li, C.T, Hsiao, Y.M, Wu, T.C, Lin, Y.W, Yeh, K.T, Ko, J.L. Vorinostat, SAHA, represses telomerase activity via epigenetic regulation of telomerase reverse transcriptase in non-small cell lung cancer cells. J. Cell Biochem. 2011, 112, 3044-3053. [CrossRef] [PubMed]
203. Zhao, Y.M, Zhou, Q, Xu, Y, Lai, X.Y, Huang, H. Antiproliferative effect of rapamycin on human T-cell leukemia cell line Jurkat by cell cycle arrest and telomerase inhibition. Acta Pharmacol. Sin. 2008, 29, 481-488. [CrossRef] [PubMed]
204. Woo, H.J, Choi, Y.H. Growth inhibition of A549 human lung carcinoma cells by beta-lapachone through induction of apoptosis and inhibition of telomerase activity. Int. J. Oncol. 2005, 26, 1017-1023. [PubMed]
205. Burger, A.M, Double, J.A, Newell, D.R. Inhibition of telomerase activity by cisplatin in human testicular cancer cells. Eur. J. Cancer 1997, 33, 638-644. [CrossRef]
206. Leon-Blanco, M.M, Guerrero, J.M, Reiter, R.J, Calvo, J.R, Pozo, D. Melatonin inhibits telomerase activity in the MCF-7 tumor cell line both in vivo and in vitro. J. Pineal. Res. 2003, 35, 204-211. [CrossRef] [PubMed]
207. Holohan, B, Hagiopian, M.M, Lai, T.P, Huang, E, Friedman, D.R, Wright, W.E, Shay, J.W. Perifosine as a potential novel anti-telomerase therapy. Oncotarget 2015, 6, 21816-21826. [CrossRef] [PubMed]
208. Baoping, Y, Guoyong, H, Jieping, Y, Zongxue, R, Hesheng, L. Cyclooxygenase-2 inhibitor nimesulide suppresses telomerase activity by blocking Akt/PKB activation in gastric cancer cell line. Dig. Dis. Sci. 2004, 49, 948-953. [CrossRef] [PubMed]
209. Kim, N.-H, Park, H.J, Oh, M.-K, Kim, I.-S. Antiproliferative effect of gold (I) compound auranofin through inhibition of STAT3 and telomerase activity in MDA-MB 231 human breast cancer cells. BMB Rep. 2013, 46, 59-64. [CrossRef] [PubMed]
210. Khorramizadeh, M.R, Saadat, F, Vaezzadeh, F, Safavifar, F, Bashiri, H, Jahanshiri, Z. Suppression of telomerase activity by pyrimethamine: Implication to cancer. Iran Biomed. J. 2007, 11, 223-228. [PubMed]
211. Brown, T, Sigurdson, E, Rogatko, A, Broccoli, D. Telomerase inhibition using azidothymidine in the HT-29 colon cancer cell line. Ann. Surg. Oncol. 2003, 10, 910-915. [CrossRef] [PubMed]
212. Gao, S, Yu, B.P, Li, Y, Dong, W.G, Luo, H.S. Antiproliferative effect of octreotide on gastric cancer cells mediated by inhibition of Akt/PKB and telomerase. World J. Gastroenterol. 2003, 9, 2362-2365. [CrossRef] [PubMed]
213. Yamakuchi, M, Nakata, M, Kawahara, K, Kitajima, I, Maruyama, I. New quinolones, ofloxacin and levofloxacin, inhibit telomerase activity in transitional cell carcinoma cell lines. Cancer Lett. 1997, 119, 213-219. [CrossRef]
214. Sun, H, Xiang, J, Li, Q, Liu, Y, Li, L, Shang, Q, Xu, G, Tang, Y. Recognize three different human telomeric G-quadruplex conformations by quinacrine. Analyst 2012, 137, 862-867. [CrossRef] [PubMed]
215. Ci, X, Li, B, Ma, X, Kong, F, Zheng, C, Björkholm, M, Jia, J, Xu, D. Bortezomibmediated down-regulation of telomerase and disruption of telomere homeostasis contributes to apoptosis of malignant cells. Oncotarget 2015, 6, 38079-38092. [PubMed]
216. Kato, M, Nakayama, M, Agata, M, Yoshida, K. Gene expression levels of human shelterin complex and shelterin-associated factors regulated by the topoisomerase II inhibitors doxorubicin and etoposide in human cultured cells. Tumour Biol. 2013, 34, 723-733. [CrossRef] [PubMed]
217. Zhang, B, Qian, D, Ma, H.H, Jin, R, Yang, P.X, Cai, M.Y, Liu, Y.H, Liao, Y.J, Deng, H.X, Mai, S.J, et al. Anthracyclines disrupt telomere maintenance by telomerase through inducing PinX1 ubiquitination and degradation. Oncogene 2012, 31, 1-12. [CrossRef] [PubMed]
218. Mimeault, M, Hauke, R, Mehta, P.P, Batra, S.K. Recent advances on cancer stem/progenitor cell research: Therapeutic implications for overcoming resistance to the most aggressive cancers. J. Mol. Cell Med. 2007, 11, 981-1011. [CrossRef] [PubMed]
219. Mimeault, M, Batra, S.K. Recent advances on the development of novel anti-cancer drugs targeting cancer stem/progenitor cells. Drug Dev. Res. 2008, 69, 415-430. [CrossRef]
220. Tang, J.Y, So, P.L, Epstein, E.H., Jr. Novel Hedgehog pathway targets against basal cell carcinoma. Toxicol. Appl. Pharmacol. 2006, 224, 257-264. [CrossRef] [PubMed]
221. Singh, B, Schneider, M, Knyazev, P, Ullrich, A. UV-induced EGFR signal transactivation is dependent on proligand shedding by activated metalloproteases in skin cancer cell lines. Int. J. Cancer 2009, 124, 531-539. [CrossRef] [PubMed]
222. Stecca, B, Mas, C, Clement, V, Zbinden, M, Correa, R, Piguet, V, Beermann, F, Ruiz, I, Altaba, A. Melanomas require HEDGEHOG-GLI signaling regulated by interactions between GLI1 and the RAS-MEK/AKT pathways. Proc. Natl. Acad. Sci. USA 2007, 104, 5895-5900. [CrossRef] [PubMed]
223. Hoffmeyer, K, Raggioli, A, Rudloff, S, Anton, R, Hierholzer, A, Del Valle, I, Hein, K, Vogt, R, Kemler, R. Wnt/β-catenin signaling regulates telomerase in stem cells and cancer cells. Science 2012, 336, 1549-1554. [CrossRef] [PubMed]
224. Calado, R.T, Young, N.S. Telomere maintenance and human bone marrow failure. Blood 2008, 111, 4446-4455. [CrossRef] [PubMed]
225. Yamamoto, K, Nihrane, A, Aglipay, J, Sironi, J, Arkin, S, Lipton, J.M, Ouchi, T, Liu, J.M. Upregulated ATM gene expression and activated DNA crosslink-induced damage response checkpoint in Fanconi anemia: Implications for carcinogenesis. Mol. Med. 2008, 14, 167-174. [CrossRef] [PubMed]
226. Meshorer, E, Gruenbaum, Y. Gone with the Wnt/Notch: Stem cells in laminopathies, progeria, and aging. J. Cell Biol. 2008, 181, 9-13. [CrossRef] [PubMed]
227. Scaffidi, P, Misteli, T. Lamin A-dependent misregulation of adult stem cells associated with accelerated ageing. Nat. Cell Biol. 2008, 10, 452-459. [CrossRef] [PubMed]
228. Bergoglio, V, Magnaldo, T. Nucleotide excision repair and related human diseases. Genome Dyn. 2006, 1, 35-52. [PubMed]
229. Stout, G.J, Blasco, M.A. Genetic dissection of the mechanisms underlying telomereassociated diseases: Impact of the TRF2 telomeric protein on mouse epidermal stem cells. Dis. Model Mech. 2009, 2, 139-156. [CrossRef] [PubMed]
230. Aubert, G, Lansdorp, P.M. Telomeres and aging. Physiol. Rev. 2008, 88, 557-579. [CrossRef] [PubMed]
231. Mason, P.J, Wilson, D.B, Bessler, M. Dyskeratosis congenital—A disease of dysfunctional telomere maintenance. Curr. Mol. Med. 2005, 5, 159-170. [CrossRef] [PubMed]
232. Kenyon, J, Gerson, S.L. The role of DNA damage repair in aging of adult stem cells. Nucleic Acids Res. 2007, 35, 7557-7565. [CrossRef] [PubMed]
233. Nijnik, A, Woodbine, L, Marchetti, C, Dawson, S, Lambe, T, Liu, C, Rodrigues, N.P, Crockford, T.L, Cabuy, E, Vindigni, A, et al. DNA repair is limiting for haematopoietic stem cells during ageing. Nature 2007, 447, 686-690. [CrossRef] [PubMed]
234. Chigancas, V, Lima-Bessa, K.M, Stary, A, Menck, C.F, Sarasin, A. Defective transcription/repair factor IIH recruitment to specific UV lesions in trichothiodystrophy syndrome. Cancer Res. 2008, 68, 6074-6083. [CrossRef] [PubMed]
235. Budiyanto, A, Bito, T, Kunisada, M, Ashida, M, Ichihashi, M, Ueda, M. Inhibition of the epidermal growth factor receptor suppresses telomerase activity in HSC-1 human cutaneous squamous cell carcinoma cells. J. Invest. Dermatol. 2003, 121, 1088-1094. [CrossRef] [PubMed]
236. Horn, S, Figl, A, Rachakonda, P.S, Fischer, C, Sucker, A, Gast, A, Kadel, S, Moll, I, Nagore, E, Hemminki, K, et al. TERT promoter mutations in familial and sporadic melanoma. Science 2013, 339, 959-961. [CrossRef] [PubMed]
237. Baur, J.A, Sinclair, D.A. Therapeutic potential of resveratrol: The in vivo evidence. Nat. Rev. Drug Discov. 2006, 5, 493-506. [CrossRef] [PubMed]
238. Athar, M, Back, J.H, Tang, X, Kim, K.H, Kopelovich, L, Bickers, D.R, Kim, A.L. Resveratrol: A review of preclinical studies for human cancer prevention. Toxicol. Appl. Pharmacol. 2007, 224, 274-283. [CrossRef] [PubMed]
239. Shay, J.W, Wright, W.E. Telomeres and telomerase in normal and cancer stem cells. FEBS Lett. 2010, 584, 3819-3825. [CrossRef] [PubMed]
240. Hahn, W.C, Counter, C.M, Lundberg, A.S, Beijersbergen, R.L, Brooks, M.W, Weinberg, R.A. Creation of human tumor cells with defined genetic elements. Nature 1999, 400, 464-468. [PubMed]
241. Braig, M, Lee, S, Loddenkemper, C, Rudolph, C, Peters, A.H, Schlegelberger, B, Stein, H, Dörken, B, Jenuwein, T, Schmitt, C.A. Oncogene-induced senescence as an initial barrier in lymphoma development. Nature 2005, 436, 660-665. [CrossRef] [PubMed]
242. Chen, Z, Trotman, L.C, Shaffer, D, Lin, H.K, Dotan, Z.A, Niki, M, Koutcher, J.A, Scher, H.I, Ludwig, T, Gerald, W, et al. Crucial role ofp53-dependent cellular senescence in suppression of Pten-deficient tumorigenesis. Nature 2005, 436, 725-730. [CrossRef] [PubMed]
243. Collado, M, Serrano, M. The power and the promise of oncogene-induced senescence markers. Nat. Rev. Cancer 2006, 6, 472-476. [CrossRef] [PubMed]
244. Xue, W, Zender, L, Miething, C, Dickins, R.A, Hernando, E, Krizhanovsky, V, Cordon-Cardo, C, Lowe, S.W. Senescence and tumour clearance is triggered by p53 restoration in murineliver carcinomas. Nature 2007, 445, 656-660. [CrossRef] [PubMed]
245. Ventura, A, Kirsch, D.G, McLaughlin, M.E, Tuveson, D.A, Grimm, J, Lintault, L, Newman, J, Reczek, E.E, Weissleder, R, Jacks, T. Restoration of p53 function leads to tumour regression in vivo. Nature 2007, 445, 661-665. [CrossRef] [PubMed]
246. Ewald, J.A, Desotelle, J.A, Wilding, G, Jarrard, D.F. Therapy-induced senescence in cancer. J. Natl. Cancer Inst. 2010, 102, 1536-1546. [CrossRef] [PubMed]
247. Te Poele, R.H, Okorokov, A.L, Jardine, L, Cummings, J, Joel, S.P. DNA damage is able to induce senescence in tumor cells in vitro and in vivo. Cancer Res. 2002, 62, 1876-1883. [PubMed]
248. Rudolph, K.L, Millard, M, Bosenberg, M.W, DePinho, R.A. Telomere dysfunction and evolution of intestinal carcinoma in mice and humans. Nat. Genet. 2001, 28, 155-159. [CrossRef] [PubMed]
249. Chin, L, Artandi, S.E, Shen, Q, Tam, A, Lee, S.-L, Gottlieb, G.J, Greider, C.W, DePinho, R.A. p53 deficiency rescues the adverse effects of telomere loss and cooperates with telomere dysfunction to accelerate carcinogenesis. Cell 1999, 97, 527-538. [CrossRef]
250. Artandi, S.E, Chang, S, Lee, S.L, Alson, S, Gottlieb, G.J, Chin, L, DePinho, R.A. Telomere dysfunction promotes non-reciprocal translocations and epithelial cancers in mice. Nature 2000, 406, 641-645. [PubMed]
251. O’Sullivan, J.N, Bronner, M.P, Brentnall, T.A, Finley, J.C, Shen, W.T, Emerson, S, Emond, M.J, Gollahon, K.A, Moskovitz, A.H, Crispin, D.A, et al. Chromosomal instability in ulcerative colitis is related to telomere shortening. Nat. Genet. 2002, 32, 280-284. [CrossRef] [PubMed]
252. Romanov, S.R, Kozakiewicz, B.K, Holst, C.R, Stampfer, M.R, Haupt, L.M, Tlsty, T.D. Normal human mammary epithelial cells spontaneously escape senescence and acquire genomic changes. Nature 2001, 409, 633-637. [CrossRef] [PubMed]
253. Seger, Y.R, García-Cao, M, Piccinin, S, Cunsolo, C.L, Doglioni, C, Blasco, M.A, Hannon, G.J, Maestro, R. Transformation of normal human cells in the absence of telomerase activation. Cancer Cell 2002, 2, 401-413. [CrossRef]
254. Tomas-Loba, A, Flores, I, Fernandez-Marcos, P.J, Cayuela, M.L, Maraver, A, Tejera, A, Borras, C, Matheu, A, Klatt, P, Flores, J.M, et al. Telomerase reverse transcriptase delays aging in cancer resistant mice. Cell 2008, 135, 609-622. [CrossRef] [PubMed]
255. Blasco, M.A. Telomeres and human disease: Ageing, cancer and beyond. Nat. Rev. Genet. 2005, 6, 611-622. [CrossRef] [PubMed]
256. Gonzalez-Suarez, E, Geserick, C, Flores, J.M, Blasco, M.A. Antagonistic effects of telomerase on cancer and aging in K5-mTert transgenic mice. Oncogene 2005, 24, 2256-2270. [CrossRef] [PubMed]
257. Bernardes de Jesus, B, Vera, E, Schneeberger, K, Tejera, A.M, Ayuso, E, Bosch, F, Blasco, M.A. Telomerase gene therapy in adult and old mice delays aging and increases longevity without increasing cancer. EMBO Mol. Med. 2012, 4, 691-704. [CrossRef] [PubMed]